Series: ASDS Annual Meeting 2019 | October 27, 2019
Integrative dermatology is growing, along with interest in the potential use of cannabinoids in dermatology. Peter Lio, MD addresses the science and the limitations of CBD.
Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of...
Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people...
New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV)...
There may indeed be a seasonality to psoriasis—if trends in online searches about the disease are an indication.
Researchers analyzed relative search volume for psoriasis and related terms in Google Trends from January 2004 to...